keyword
MENU ▼
Read by QxMD icon Read
search

Finasteride

keyword
https://www.readbyqxmd.com/read/28499916/effects-of-neonatal-and-adolescent-neuroactive-steroid-manipulation-on-locomotor-activity-induced-by-ethanol-in-male-wistar-rats
#1
Iris Bartolomé, Anna Llidó, Sònia Darbra, Marc Pallarès
Neonatal neuroactive steroids levels are crucial for brain development. Alterations of neonatal neuroactive steroids levels induce anxiolytic-like effects and improve exploration in novel environments in adulthood. These behavioural traits, i.e. sensation/novelty seeking, anxiety or impulsivity, are associated with vulnerability to drug use and abuse. Adolescence is also recognized as a particularly critical developmental phase to contribute to vulnerable phenotype. However, the influence of neuroactive steroids during development in the vulnerability to drug addiction has been poorly studied...
May 9, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28493523/fibrillar-collagen-genes-are-not-co-ordinately-up-regulated-with-tgf-%C3%AE-1-expression-in-finasteride-treated-prostate
#2
Flávia Karina Delella, Fernanda Losi Alves de Almeida, Helga Caputo Nunes, Jaqueline Carvalho Rinaldi, Sérgio Luis Felisbino
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms (LUTS) in older men. In this regard, recent studies have attempted to define the relationships between prostatic fibrosis, LUTS, and increased expression of transforming growth factor β1 (TGF β1) in BHP. Therapeutic approaches for BPH such as 5-α-reductase inhibitors and alpha-adrenergic blocking agents increase TGF β1 expression in the prostatic tissue. Here, we investigated the effects of the 5-α-reductase inhibitor-finasteride-on rat ventral prostate tissue, especially with regard to the tissue distribution and gene expression of fibrillar collagens...
May 11, 2017: Cell Biology International
https://www.readbyqxmd.com/read/28487578/5%C3%AE-reductase-inhibitors-for-treatment-of-benign-prostatic-hyperplasia-a-systematic-review-and-meta-analysis
#3
REVIEW
Jennifer E J Jun, Angus Kinkade, Anthony C H Tung, Aaron M Tejani
BACKGROUND: Finasteride and dutasteride are competitive inhibitors of 5α-reductase enzymes and are commonly used to treat symptomatic benign prostatic hyperplasia (BPH). OBJECTIVE: To compare the efficacy and safety of finasteride and dutasteride in terms of clinically important outcomes. DATA SOURCES: A literature search was performed using the search terms "prostatic hyperplasia", "prostatic hypertrophy", "dutasteride", "finasteride", "quality of life", "adverse drug reaction", and "mortality"...
March 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28453908/sexual-dysfunction-in-subjects-treated-with-inhibitors-of-5%C3%AE-reductase-for-benign-prostatic-hyperplasia-a-comprehensive-review-and-meta-analysis
#4
REVIEW
G Corona, G Tirabassi, D Santi, E Maseroli, M Gacci, M Dicuio, A Sforza, E Mannucci, M Maggi
Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'...
April 28, 2017: Andrology
https://www.readbyqxmd.com/read/28452419/neurosteroid-sensitive-%C3%AE-gabaa-receptors-a-role-in-epileptogenesis
#5
Suchitra Joshi, Karthik Rajasekaran, John Williamson, Jaideep Kapur
OBJECTIVE: We determined the role of the neurosteroid-sensitive δ subunit-containing γ-aminobutyric acid A receptors (δ-GABARs) in epileptogenesis. METHODS: Status epilepticus (SE) was induced via lithium pilocarpine in adult rats, and seizures were assessed by continuous video-electroencephalography (EEG) monitoring. Finasteride was administered to inhibit neurosteroid synthesis. The total and surface protein expression of hippocampal δ, α4, and γ2 GABAR subunits was studied using biotinylation assays and Western blotting...
March 2017: Epilepsia
https://www.readbyqxmd.com/read/28450835/bioactives-in-chinese-proprietary-medicine-modulates-5%C3%AE-reductase-activity-and-gene-expression-associated-with-androgenetic-alopecia
#6
Justin J Y Tan, Jing Pan, Lihan Sun, Junying Zhang, Chunyong Wu, Lifeng Kang
Androgenetic alopecia (AGA) is characterized by a progressive and patterned transformation of thick, pigmented terminal scalp hairs into short, hypo-pigmented vellus-like hairs. The use of Minoxidil and Finasteride to treat AGA are often associated with complications in safety and efficacy. However, herbal remedies are deemed to have lesser side effects in many societies. This study aims to identify potential hair growth properties of individual compounds from a Chinese proprietary medicine known as Yangxue Shengfa capsule (YSC), used in China for many years for improving AGA...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28416373/inhibition-effects-of-chlorogenic-acid-on-benign-prostatic-hyperplasia-in-mice
#7
Ya Huang, Huaguo Chen, Xin Zhou, Xingdong Wu, Enming Hu, Zhengmeng Jiang
This study aimed to evaluate the inhibitory effects and explore mechanisms of chlorogenic acid against testosterone-induced benign prostatic hyperplasia (BPH) in mice. Benign prostatic hyperplasia model was induced in experimental groups by daily subcutaneous injections of testosterone propionate (7.5mg/kg/d) consecutively for 14 d. A total of 60 mice were randomly divided into six groups: (Group 1) normal control group, (Group 2) benign prostatic hyperplasia model control group, (Group 3) benign prostatic hyperplasia mice treated with finasteride at a dose of 1mg/kg, (Group 4) benign prostatic hyperplasia mice treated with chlorogenic acid at dose levels of 0...
April 14, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28408350/neuroactive-steroid-levels-and-psychiatric-and-andrological-features-in-post-finasteride-patients
#8
Roberto Cosimo Melcangi, Daniele Santi, Roberto Spezzano, Maria Grimoldi, Tommaso Tabacchi, Maria Letizia Fusco, Silvia Diviccaro, Silvia Giatti, Giuseppe Carrà, Donatella Caruso, Manuela Simoni, Guido Cavaletti
Recent reports show that, in patients treated with finasteride for male pattern hair loss, persistent side effects including sexual side effects, depression, anxiety and cognitive complaints may occur. We here explored the psychiatric and andrological features of patients affected by post-finasteride syndrome (PFS) and verified whether the cerebrospinal fluid (CSF) and plasma levels of neuroactive steroids (i.e., important regulators of nervous function) are modified. We found that eight out of sixteen PFS male patients considered suffered from a DSM-IV major depressive disorder (MDD)...
April 10, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28407365/role-of-allopregnanolone-biosynthesis-in-acute-stress-induced-anxiety-like-behaviors-in-mice
#9
Kazumi Yoshizawa, Ayano Okumura, Kozue Nakashima, Tomoyo Sato, Tatsuya Higashi
The neurosteroid allopregnanolone (3α, 5α-tetra-hydroprogesterone: ALLO) elicits anxiolytic, anticonvulsant, and hypnotic anesthetic effects in vivo similar to those induced by other positive allosteric modulators of the GABAA receptor. Endogenous ALLO has been shown to be rapidly elevated in the brain by acute stress paradigms, such as immobilization, in animal models. The present study was designed to ascertain the role of neurosteroid biosynthesis in the anxiety-like behavior induced by immobilization stress...
April 13, 2017: Synapse
https://www.readbyqxmd.com/read/28396101/the-effectiveness-of-treatments-for-androgenetic-alopecia-a-systematic-review-and-meta-analysis
#10
REVIEW
Areej Adil, Marshall Godwin
BACKGROUND: Androgenetic alopecia, or male pattern hair loss, is a hair loss disorder mediated by dihydrotestosterone, the potent form of testosterone. Currently, minoxidil and finasteride are Food and Drug Administration (FDA)-approved, and HairMax LaserComb, which is FDA-cleared, are the only treatments recognized by the FDA as treatments of androgenetic alopecia. OBJECTIVE: This systematic review and meta-analysis assesses the efficacy of nonsurgical treatments of androgenetic alopecia in comparison to placebo for improving hair density, thickness, growth (defined by an increased anagen:telogen ratio), or subjective global assessments done by patients and investigators...
April 7, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28393993/-finasteride-adverse-effects-an-update
#11
Néstor Carreño-Orellana, Catherina Moll-Manzur, Juan Eduardo Carrasco-Zuber, Sergio Álvarez-Véliz, Daniela Berroeta-Mauriziano, Ninoska Porras-Kusmanic
Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. The aim of this article is to clarify the controversies about the safety of finasteride by analyzing the evidence available in the literature.
December 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28391389/combination-therapy-with-omega-3-fatty-acids-plus-tamsulocin-and-finasteride-in-the-treatment-of-men-with-lower-urinary-tract-symptoms-luts-and-benign-prostatic-hyperplasia-bph
#12
Alireza Ghadian, Mehran Rezaei
PURPOSE: Inflammation and Cyclooxygenase-2 (COX-2) as a part of it are common in BPH specimens and may play a role in the pathogenesis of the disease through cytokines that promote cell growth or lead to smooth muscle contraction. The aim of this study is to analyze whether combination therapy with omega-3 fatty acids, which have anti-inflammatory and COX-2 inhibitory effects, and tamsulocin plus finasteride offers an advantage compared to tamsulocin plus finasteride therapy in patients with BPH...
April 8, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28385453/co-clinical-analysis-of-a-genetically-engineered-mouse-model-and-human-prostate-cancer-reveals-significance-of-nkx3-1-expression-for-response-to-5%C3%AE-reductase-inhibition
#13
Aditya Dutta, Sukanya Panja, Renu K Virk, Jaime Yeji Kim, Roseann Zott, Serge Cremers, David M Golombos, Deli Liu, Juan Miguel Mosquera, Elahe A Mostaghel, Christopher E Barbieri, Antonina Mitrofanova, Cory Abate-Shen
BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed...
April 3, 2017: European Urology
https://www.readbyqxmd.com/read/28360960/clomiphene-citrate-rescue-of-spermatogenesis-in-men-with-infertility-while-remaining-on-finasteride-a-case-report
#14
Christopher Wu, Ellen Forbes, Keith Allen Jarvi
No abstract text is available yet for this article.
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28338531/hormonal-manipulation-with-finasteride-or-oral-contraception-does-not-influence-incidence-of-renal-cell-carcinoma
#15
Aashish Kabra, Jonathan Gelfond, Michael A Liss
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy...
March 23, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28338402/testosterone-plus-finasteride-prevents-bone-loss-without-prostate-growth-in-a-rodent-spinal-cord-injury-model
#16
Joshua F Yarrow, Ean G Phillips, Christine F Conover, Taylor E Bassett, Cong Chen, Tyler Teurlings, Andrea Vasconez, Jonathan Alerte, Hannah M Prock, Jessica M Jiron, Micah Flores, J Ignacio Aguirre, Stephen E Borst, Fan Ye
We have reported that testosterone-enanthate (TE) prevents the musculoskeletal decline occurring acutely after spinal cord injury (SCI), but results in a near doubling of prostate mass. Our purpose was to test the hypothesis that administration of TE plus finasteride (FIN, type II 5α-reductase inhibitor) would prevent the chronic musculoskeletal deficits in our rodent severe contusion SCI model, without inducing prostate enlargement. Forty-three 16-week old male Sprague-Dawley rats received: (1) SHAM surgery (T9 laminectomy), (2) severe (250 kdyne) contusion SCI, (3) SCI+TE (7...
March 24, 2017: Journal of Neurotrauma
https://www.readbyqxmd.com/read/28319231/association-of-suicidality-and-depression-with-5%C3%AE-reductase-inhibitors
#17
Blayne Welk, Eric McArthur, Michael Ordon, Kelly K Anderson, Jade Hayward, Stephanie Dixon
Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013)...
May 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28317149/association-between-variants-in-genes-involved-in-the-immune-response-and-prostate-cancer-risk-in-men-randomized-to-the-finasteride-arm-in-the-prostate-cancer-prevention-trial
#18
Danyelle A Winchester, Cathee Till, Phyllis J Goodman, Catherine M Tangen, Regina M Santella, Teresa L Johnson-Pais, Robin J Leach, Jianfeng Xu, S Lilly Zheng, Ian M Thompson, M Scott Lucia, Scott M Lippman, Howard L Parnes, William B Isaacs, Angelo M De Marzo, Charles G Drake, Elizabeth A Platz
BACKGROUND: We reported that some, but not all single nucleotide polymorphisms (SNPs) in select immune response genes are associated with prostate cancer, but not individually with the prevalence of intraprostatic inflammation in the Prostate Cancer Prevention Trial (PCPT) placebo arm. Here, we investigated whether these same SNPs are associated with risk of lower- and higher-grade prostate cancer in men randomized to finasteride, and with prevalence of intraprostatic inflammation among controls...
June 2017: Prostate
https://www.readbyqxmd.com/read/28301260/cancer-targeting-potential-of-99m-tc-finasteride-in-experimental-model-of-prostate-carcinogenesis
#19
Gowsia Jan, Neelima D Passi, Devinder Kumar Dhawan, Vijayta Dani Chadha
This study aimed to radiolabel finasteride, a novel 5α-reductase inhibitor, to evaluate its cancer targeting potential in experimental model of prostate carcinogenesis. Finasteride was effectively radiolabeled with (99m)Tc and showed >90% labeling efficiency. The radiopharmaceutical was found to be stable up to 6 hours in rat serum at 37°C. The blood kinetics of the (99m)Tc-finasteride followed a biphasic release pattern, whereby fast-release phase was observed at 15 seconds and a slow-release phase was observed after 30 minutes of administration...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28300347/assessing-finasteride-associated-sexual-dysfunction-using-the-faers-database
#20
A K Gupta, J Carviel, M A MacLeod, N Shear
BACKGROUND: Postmarketing reports suggest that finasteride causes sexual dysfunction despite a low incidence reported in clinical trials. Therefore, the extent of risk remains unknown. OBJECTIVE: To determine whether the risk of sexual dysfunction is higher among individuals treated with finasteride compared to a baseline risk for all other drugs using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: A case by non-case disproportionality approach was used whereby a reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated...
March 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
11512
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"